Ocrelizumab Phase IIIb Efficacy: 2-Year NEDA Rates With MRI Re-Baselining From the CASTING Study in Relapsing-Remitting MS Patients With a Suboptimal Response to Prior DMTs

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2020
This article has no abstract
Epistemonikos ID: b6f3296cd271895471ed385f5871a653d43c5063
First added on: Feb 12, 2025